Publikationen

 

Aggressive Lymphome

• Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma.
  Bishop MR, Dickinson M, Purtill D, Barba P, Santoro A, Hamad N, Kato K, Sureda A, Greil R, Thieblemont C, Morschhauser F, Janz M, Flinn I, Rabitsch W, Kwong YL, Kersten MJ, Minnema MC, Holte H, Chan EHL, Martinez-Lopez J, Müller AMS, Maziarz RT, McGuirk JP, Bachy E, Le Gouill S, Dreyling M, Harigae H, Bond D, Andreadis C, McSweeney P, Kharfan-Dabaja M, Newsome S, Degtyarev E, Awasthi R, Del Corral C, Andreola G, Masood A, Schuster SJ, Jäger U, Borchmann P, Westin JR.
  N Engl J Med. 2021 Dec 14. (Online ahead of print).     PMID: 34904798 DOI: 10.1056/NEJMoa2116596
• Identification of the atypically modified autoantigen Ars2 as the target of B-cell receptors from activated B cell–type diffuse large B-cell lymphoma
  Lorenz Thurner, Sylvia Hartmann, Moritz Bewarder, Natalie Fadle, Evi Regitz, Claudia Schormann, Natalia Quiroga, Maria Kemele, Wolfram Klapper, Andreas Rosenwald, Rainer Maria Bohle, Lorenz Trümper, Anna Nimmesgern, Christina Körbel, Matthias W. Laschke, Michael D. Menger, Stefan Barth, Boris Kubuschok, Anja Mottok, Dominic Kaddu-Mulindwa, Martin-Leo Hansmann, Viola Pöschel, Gerhard Held, Niels Murawski, Stephan Stilgenbauer, Frank Neumann, Klaus-Dieter Preuss, and Michael Pfreundschuh.
  Haematologica, 2021 Aug 1;106(8):2224-2232 PMID: 32675228 PMCID: PMC8327713 DOI: 10.3324/haematol.2019.241653
• FDG PET/CT to detect bone marrow involvement in the initial staging of patients with aggressive non-Hodgkin lymphoma: results from the prospective, multicenter PETAL and OPTIMAL>60 trials.
  Kaddu-Mulindwa D, Altmann B, Held G, Angel S, Stilgenbauer S, Thurner L, Bewarder M, Schwier M, Pfreundschuh M, Löffler M, Menhart K, Grosse J, Ziepert M, Herrmann K, Dührsen U, Hüttmann A, Barbato F, Poeschel V, Hellwig D.
  Eur J Nucl Med Mol Imaging. 2021 Apr 29. PMID: 33928400 PMCID: PMC8440256 DOI: 10.1007/s00259-021-05348-6
• Rituximab plus high-dose chemotherapy (MegaCHOEP) or conventional chemotherapy (CHOEP-14) in young, high-risk patients with aggressive B-cell lymphoma: 10-year follow-up of a randomised, open-label, phase 3 trial.
  Frontzek, F.*, Ziepert, M.*, Nickelsen, M., Altmann, B., Glass, B., Haenel, M., Truemper, L., Held, G., Bentz, M., Borchmann, P., Dreyling, M., Viardot, A., Kroschinsky, FP., Metzner, B., Staiger, AM., Horn, H., Ott, G., Rosenwald, A., Loeffler, M., Lenz, G. and Schmitz, N. (2021):
  Lancet Haematol. e267-e277. PMID: 33667420 DOI: 10.1016/S2352-3026(21)00022-3
• SPARC-positive macrophages are the superior prognostic factor in the microenvironment of diffuse large B-cell lymphoma and independent of MYC rearrangement and double-/triple-hit status.
  Croci, GA.*, Au-Yeung, RKH.*, Reinke, S., Staiger, AM., Koch, K., Oschlies, I., Richter, J., Poeschel, V., Held, G., Loeffler, M., Trümper, L., Rosenwald, A., Ott, G., Spang, R., Altmann, B., Ziepert, M.* and Klapper, W.* (2021):  
  Ann Oncol. 32(11), 1400-09. PMID: 34438040 DOI: 10.1016/j.annonc.2021.08.1991
• Relapsed/Refractory International Prognostic Index (R/R-IPI): An international prognostic calculator for relapsed/refractory diffuse large B-cell lymphoma.
  Maurer, MJ., Jakobsen, LH., Mwangi, R., Schmitz, N., Farooq, U., Flowers, CR., de Nully Brown, P., Thompson, CA., Frederiksen, H., Cunningham, D., Jørgensen, J., Poeschel, V., Nowakowski, G., Seymour, JF., Merli, F., Haioun, C., Ghesquieres, H., Ziepert, M., Tilly, H., Salles, G., Shi, Q., El-Galaly, TC. and Habermann, TM. (2021):  Am J Hematol. 96(5), 599-605. PMID: 33661547 DOI: 10.1002/ajh.26149
• Polatuzumab vedotin as a salvage and bridging treatment in relapsed or refractory large B-cell lymphomas.
  Liebers N, Duell J, Fitzgerald D, Kerkhoff A, Noerenberg D, Kaebisch E, Acker F, Fuhrmann S, Leng C, Welslau M, Chemnitz J, Middeke JM, Weber T, Holtick U, Trappe R, Pfannes R, Liersch R, Spoer C, Fuxius S, Gebauer N, Caillé L, Geer T, Koenecke C, Keller U, Claus R, Mougiakakos D, Mayer S, Huettmann A, Pott C, Trummer A, Wulf G, Brunnberg U, Bullinger L, Hess G, Mueller-Tidow C, Glass B, Lenz G, Dreger P, Dietrich S.
  Blood Adv. 2021 PMID: 34196677 PMCID: PMC8288676 DOI: 10.1182/bloodadvances.2020004155
• CAR-HEMATOTOX: A model for CAR T-cell related hematological toxicity in relapsed/refractory large B-cell lymphoma. Rejeski K, Perez Perez A, Sesques P, Hoster E, Berger CS, Jentzsch L, Mougiakakos D, Frölich L, Ackermann J, Buecklein V, Blumenberg V, Schmidt C, Jallades L, Fehse B, Faul C, Karschnia P, Weigert O, Dreyling M, Locke FL, von Bergwelt-Baildon M, Mackensen A, Bethge WA, Ayuk F, Bachy E, Salles GA, Jain MD, Subklewe M. Blood. 2021 Jun 24:blood.2020010543. Online ahead of print. https://doi.org/10.1182/blood.2020010543
• Long-term outcomes from the phase II L-MIND study of tafasitamab (MOR208) plus lenalidomide in patients with relapsed or refractory diffuse large B-cell lymphoma
  Duell J, Maddocks KJ, González-Barca E, Jurczak W, Liberati AM, De Vos S, Nagy Z, Obr A, Gaidano G, Abrisqueta P, Kalakonda N, André M, Dreyling M, Menne T, Tournilhac O, Augustin M, Rosenwald A, Dirnberger-Hertweck M, Weirather J, Ambarkhane S, Salles G.  Haematologica. 2021 Aug 19. Online ahead of print.PMID: 34196165 PMCID: PMC8409029 DOI: 10.3324/haematol.2020.275958

 

Indolente Lymphome

• Treatment dependence of prognostic gene expression signatures in de novo follicular lymphoma.
  Bolen CR, Mattiello F, Herold M, Hiddemann W, Huet S, Klapper W, Marcus R, Mir F, Salles G, Weigert O, Nielsen T, Oestergaard MZ, Venstrom JM. Blood. 2021 May 13;137(19):2704-2707. doi: 10.1182/blood.2020008119. PMID: 33512481
• Evaluating upfront high-dose consolidation after R-CHOP for follicular lymphoma by clinical and genetic risk models.
  Alig S, Jurinovic V, Shahrokh Esfahani M, Haebe S, Passerini V, Hellmuth JC, Gaitzsch E, Keay W, Tahiri N, Zoellner A, Rosenwald A, Klapper W, Stein H, Feller A, Ott G, Staiger AM, Horn H, Hansmann ML, Pott C, Unterhalt M, Schmidt C, Dreyling M, Alizadeh AA, Hiddemann W, Hoster E, Weigert O.
  Blood Adv. 2020 Sep 22;4(18):4451-4462. doi: 10.1182/bloodadvances.2020002546. PMID: 32941649 Free PMC article. Clinical Trial.
• Cathepsin S Alterations Induce a Tumor-Promoting Immune Microenvironment in Follicular Lymphoma.
  Bararia D, Hildebrand JA, Stolz S, Haebe S, Alig S, Trevisani CP, Osorio-Barrios F, Bartoschek MD, Mentz M, Pastore A, Gaitzsch E, Heide M, Jurinovic V, Rautter K, Gunawardana J, Sabdia MB, Szczepanowski M, Richter J, Klapper W, Louissaint A Jr, Ludwig C, Bultmann S, Leonhardt H, Eustermann S, Hopfner KP, Hiddemann W, von Bergwelt-Baildon M, Steidl C, Kridel R, Tobin JWD, Gandhi MK, Weinstock DM, Schmidt-Supprian M, Sárosi MB, Rudelius M, Passerini V, Mautner J, Weigert O.
  Cell Rep. 2020 May 5;31(5):107522. doi: 10.1016/j.celrep.2020.107522. Epub 2020 Apr 23. PMID: 32330423
• Localized- and advanced-stage follicular lymphomas differ in their gene expression profiles.
  Staiger AM, Hoster E, Jurinovic V, Winter S, Leich E, Kalla C, Möller P, Bernd HW, Feller AC, Koch K, Klapper W, Stein H, Hansmann ML, Hartmann S, Dreyling M, Weigert O, Hiddemann W, Herfarth K, Rosenwald A, Engelhard M, Ott G, Horn H.
  Blood. 2020 Jan 16;135(3):181-190. doi: 10.1182/blood.2019000560. PMID: 31697802 Clinical Trial.
• Newly diagnosed and relapsed follicular lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
  Dreyling M, Ghielmini M, Rule S, Salles G, Ladetto M, Tonino SH, Herfarth K, Seymour JF, Jerkeman M; ESMO Guidelines Committee Ann Oncol. 2021 Mar;32(3):298-308
• Efficacy and safety of copanlisib in patients with relapsed or refractory marginal zone lymphoma.  
  Panayiotidis P, Follows GA, Mollica L, Nagler A, Özcan M, Santoro A, Stevens D, Trevarthen D, Hiemeyer F, Garcia-Vargas J, Childs BH, Zinzani PL, Dreyling M.
  Blood Adv. 2021 Feb 9;5(3):823-828 PMID: 33560394 PMCID: PMC7876879 DOI: 10.1182/bloodadvances.2020002910
• Efficacy and safety assessment of prolonged maintenance with subcutaneous rituximab in patients with relapsed or refractory indolent non-Hodgkin lymphoma: results of the Phase III MabCute study
  Rule S, Barreto WG, Briones J, Carella AM, Casasnovas O, Pocock C, Wendtner CM, Zaja F, Robson S, MacGregor L, Tschopp RR, Nick S, Dreyling M..  Haematologica. 2021 Jun 17. Online ahead of print PMID: 34134469 DOI: 10.3324/haematol.2020.274803
• Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial.
  Fowler NH, Dickinson M, Dreyling M, Martinez-Lopez J, Kolstad A, Butler J, Ghosh M, Popplewell L, Chavez JC, Bachy E, Kato K, Harigae H, Kersten MJ, Andreadis C, Riedell PA, Ho PJ, Pérez-Simón JA, Chen AI, Nastoupil LJ, von Tresckow B, Ferreri AJM, Teshima T, Patten PEM, McGuirk JP, Petzer AL, Offner F, Viardot A, Zinzani PL, Malladi R, Zia A, Awasthi R, Masood A, Anak O, Schuster SJ, Thieblemont C.
  Nat Med. 2021 Dec 17. (Online ahead of print)
• Long-term efficacy and safety of CT-P10 or rituximab in untreated advanced follicular lymphoma: a randomized phase 3 study.
  Buske C, Jurczak W, Sancho JM, Zhavrid E, Kim JS, Hernández-Rivas JÁ, Prokharau A, Vasilica M, Nagarkar R, Kwak L, Kim WS, Lee S, Kim S, Ahn K, Ogura M.Blood Adv. 2021 Sep 14;5(17):3354-3361
  PMID: 34477816 PMCID: PMC8525228 DOI: 10.1182/bloodadvances.2021004484

• Single-Agent Ibrutinib for Rituximab-Refractory Waldenström Macroglobulinemia: Final Analysis of the Substudy of the Phase III InnovateTM Trial.
  Trotman J, Buske C, Tedeschi A, Matous JV, MacDonald D, Tam CS, Tournilhac O, Ma S, Treon SP, Oriol A, Ping J, Briso EM, Arango-Hisijara I, Dimopoulos MA.Clin Cancer Res. 2021 Nov 1;27(21):5793-5800.
  PMID: 34380643 DOI: 10.1158/1078-0432.CCR-21-1497

•  

  Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial.
  Dimopoulos M, Sanz RG, Lee HP, Trneny M, Varettoni M, Opat S, D'Sa S, Owen RG, Cull G, Mulligan S, Czyz J, Castillo JJ, Motta M, Siddiqi T, Gironella Mesa M, Granell Gorrochategui M, Talaulikar D, Zinzani PL, Askari E, Grosicki S, Oriol A, Rule S, Kloczko J, Tedeschi A, Buske C, Leblond V, Trotman J, Chan WY, Michel J, Schneider J, Tan Z, Cohen A, Huang J, Tam CS.Blood Adv. 2020 Dec 8;4(23):6009-6018.
  PMID: 33284944 PMCID: PMC7724905 DOI: 10.1182/bloodadvances.2020003010

 

 

Mantelzelllymphome

• LRPAP1 autoantibodies in mantle cell lymphoma are associated with superior outcome
  Thurner L, Fadle N, Bittenbring JT, Regitz E, Schuck R, Cetin O, Stuhr A, Rixecker T, Murawski N, Poeschel V, Kaddu-Mulindwa D, Preuss KD, Stilgenbauer S, Hermine O, Kluin-Nelemans HC, Hartmann S, Dreyling M, Pott C, Bewarder M, Hoster E. 
  Blood. 2021 Jun 10;137(23):3251-3258 PMID: 33513604 PMCID: PMC8351899 (available on 2022-06-10) DOI: 10.1182/blood.2020008835
• The B-cell Receptor Autoantigen LRPAP1 Can Replace Variable Antibody Regions to Target Mantle Cell Lymphoma Cells.
  Bewarder M, Kiefer M, Will H, Olesch K, Moelle C, Stilgenbauer S, Christofyllakis K, Kaddu-Mulindwa D, Bittenbring JT, Fadle N, Regitz E, Kaschek L, Hoth M, Neumann F, Preuss KD, Pfreundschuh M, Thurner L.
  Hemasphere. 2021 Jul 13;5(8):e620. PMID: 34263144 PMCID: PMC8274796 DOI: 10.1097/HS9.0000000000000620
• The impact of SAMHD1 expression and mutation status in mantle cell lymphoma: An analysis of the MCL Younger and Elderly trial.
  Roider T, Wang X, Hüttl K, Müller-Tidow C, Klapper W, Rosenwald A, Stewart JP, de Castro DG, Dreger P, Hermine O, Kluin-Nelemans HC, Grabe N, Dreyling M, Pott C, Ott G, Hoster E, Dietrich S.
  Int J Cancer. 2021      PMID: 32638373 DOI: 10.1002/ijc.33202
• Mantle cell lymphoma - advances in molecular biology, prognostication and treatment approaches.
  Silkenstedt E, Linton K, Dreyling M.
  Br J Haematol. 2021 Mar 30 Online ahead of print.      PMID: 33783838 DOI: 10.1111/bjh.17419
• Long-term survival of patients with mantle cell lymphoma after autologous haematopoietic stem-cell transplantation in first remission: a post-hoc analysis of an open-label, multicentre, randomised, phase 3 trial.
  Zoellner AK, Unterhalt M, Stilgenbauer S, Hübel K, Thieblemont C, Metzner B, Topp M, Truemper L, Schmidt C, Bouabdallah K, Krauter J, Lenz G, Dürig J, Vergote V, Schäfer-Eckart K, André M, Kluin-Nelemans HC, van Hoof A, Klapper W, Hiddemann W, Dreyling M, Hoster E; European Mantle Cell Lymphoma Network.   Lancet Haematol. 2021 Sep;8(9):e648-e657.
• ASTCT, CIBMTR, and EBMT clinical practice recommendations for transplant and cellular therapies in mantle cell lymphoma
  Munshi PN, Hamadani M, Kumar A, Dreger P, Friedberg JW, Dreyling M, Kahl B, Jerkeman M, Kharfan-Dabaja MA, Locke FL, Shadman M, Hill BT, Ahmed S, Herrera AF, Sauter CS, Bachanova V, Ghosh N, Lunning M, Kenkre VP, Aljurf M, Wang M, Maddocks KJ, Leonard JP, Kamdar M, Phillips T, Cashen AF, Inwards DJ, Sureda A, Cohen JB, Smith SM, Carlo-Stella C, Savani B, Robinson SP, Fenske TS.
  Bone Marrow Transplant. 2021 Aug 20. Online ahead of print.

 

T-Zell-Lymphome

• A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL
  Schmitz, N., Truemper, L., Bouabdallah, K., Ziepert, M., Leclerc, M., Cartron, G., Jaccard, A., Reimer, P., Wagner, E., Wilhelm, M., Sanhes, L., Lamy, T., de Leval, L., Rosenwald, A., Roussel, M., Kroschinsky, F., Lindemann, W., Dreger, P., Viardot, A., Milpied, N., Gisselbrecht, C., Wulf, G., Gyan, E., Gaulard, P., Bay, JO., Glass, B., Poeschel, V., Damaj, G., Sibon, D., Delmer, A., Bilger, K., Banos, A., Haenel, M., Dreyling, M., Metzner, B., Keller, U., Braulke, F., Friedrichs, B., Nickelsen, M., Altmann, B.* and Tournilhac, O.* (2021):
  Blood. 137(19), 2646-56.     PMID: 33512419 DOI: 10.1182/blood.2020008825
• Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial
  Wulf GG, Altmann B, Ziepert M, D'Amore F, Held G, Greil R, Tournilhac O, Relander T, Viardot A, Wilhelm M, Wilhelm C, Pezzutto A, Zijlstra JM, Neste EVD, Lugtenburg PJ, Doorduijn JK, Gelder MV, van Imhoff GW, Zettl F, Braulke F, Nickelsen M, Glass B, Rosenwald A, Gaulard P, Loeffler M, Pfreundschuh M, Schmitz N, Trümper L; ACT-2 study investigators.  
  Leukemia. 2021 Jan;35(1):143-155. doi: 10.1038/s41375-020-0838-5. Epub 2020 May 7. PMID: 32382083.
• A randomized phase 3 trial of autologous vs allogeneic transplantation as part of first-line therapy in poor-risk peripheral T-NHL
  Schmitz N, Truemper L, Bouabdallah K, Ziepert M, Leclerc M, Cartron G, Jaccard A, Reimer P, Wagner E, Wilhelm M, Sanhes L, Lamy T, de Leval L, Rosenwald A, Roussel M, Kroschinsky F, Lindemann W, Dreger P, Viardot A, Milpied N, Gisselbrecht C, Wulf G, Gyan E, Gaulard P, Bay JO, Glass B, Poeschel V, Damaj G, Sibon D, Delmer A, Bilger K, Banos A, Haenel M, Dreyling M, Metzner B, Keller U, Braulke F, Friedrichs B, Nickelsen M, Altmann B, Tournilhac O.
  Blood. 2021 May 13;137(19):2646-2656. doi: 10.1182/blood.2020008825. PMID: 33512419.

 

ZNS-Lymphome

• Integration of the B-cell Receptor Antigen Neurabin-I/SAMD14 into an Antibody Format as New Therapeutic Approach for the Treatment of Primary CNS Lymphoma.
  Moritz Bewarder, Lisa Goerens, Clara Moelle, Maximilian Kiefer, Stephan Stilgenbauer, Konstantinos Christofyllakis, Dominic Kaddu-Mulindwa, Natalie Fadle, Evi Regitz, Frank Neumann, Klaus-Dieter Preuss, Michael Pfreundschuh and Lorenz Thurner.  Accepted October 2020 in Frontiers Oncology
  PMID: 33282736 PMCID: PMC7689012 DOI: 10.3389/fonc.2020.580364
• Treatment Regiments for Immunocompetent Elderly Patients with Primary Central Nervous System Lymphoma: A Scoping Review
  Schorb E, Isbell LK, Illerhaus G, Ihorst G, Meerpohl JJ, Grummich K, Nagavci B, Schmucker C.
  Cancers (Basel) 2021 Aug      PMID: 34503078 PMCID: PMC8428349 DOI: 10.3390/cancers13174268
• Consensus recommendations for MRI and PET imaging of primary central nervous system lymphoma: guideline statement from the International Primary CNS Lymphoma Collaborative Group (IPCG)
  Barajas RF, Politi LS, Anzalone N, Schöder H, Fox CP, Boxerman JL, Kaufmann TJ, Quarles CC, Ellingson BM, Auer D, Andronesi OC, Ferreri AJM, Mrugala MM, Grommes C, Neuwelt EA, Ambady P, Rubenstein JL, Illerhaus G, Nagane M, Batchelor TT, Hu LS. Neuro Oncol. 2021 Jul     
  PMID: 33560416 PMCID: PMC8248856 DOI: 10.1093/neuonc/noab020
• CNS relapse in DLBCL: a calculable risk?
  Illerhaus G
  Blood. 2021 Feb 25;137(8):1120-1124. doi: 10.1182/blood.2020007236. PMID: 32877514
• Analysis of Driver Mutational Hot Spots in Blood-Derived Cell-Free DNA of Patients with Primary Central Nervous System Lymphoma Obtained before Intracerebral Biopsy.
  Montesinos-Rongen M, Brunn A, Tuchscherer A, Borchmann P, Schorb E, Kasenda B, Altmüller J, Illerhaus G, Ruge MI, Maarouf M, Büttner R, Hansmann ML, Hallek M, Prinz M, Siebert R, Deckert M.
  J Mol Diagn. 2020 Oct     PMID: 32745612 DOI: 10.1016/j.jmoldx.2020.07.002                            
• High-dose chemotherapy and autologous stem cell transplant in elderly patients with primary CNS lymphoma: a pilot study
  Schorb E, Kasenda B, Ihorst G, Scherer F, Wendler J, Isbell L, Fricker H, Finke J, Illerhaus G.
  Blood Adv. 2020 Jul      PMID: 32722778 PMCID: PMC7391148 DOI: 10.1182/bloodadvances.2020002064
• Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis.
  Lauer EM, Waterhouse M, Braig M, Mutter J, Bleul S, Duque-Afonso J, Duyster J, Marks R, Reinacher PC, Prinz M, Illerhaus G, Finke J, Schorb E, Scherer F.
  Br J Haematol. 2020 Jul         PMID: 32452526 DOI: 10.1111/bjh.16759
• Induction therapy with the MATRix regimen in patients with newly diagnosed primary diffuse large B-cell lymphoma of the central nervous system - an international study of feasibility and efficacy in routine clinical practice.
  Schorb E, Fox CP, Kasenda B, Linton K, Martinez-Calle N, Calimeri T, Ninkovic S, Eyre TA, Cummin T, Smith J, Yallop D, De Marco B, Krampera M, Trefz S, Orsucci L, Fabbri A, Illerhaus G, Cwynarski K, Ferreri AJM.
  Br J Haematol. 2020 Jun             PMID: 31997308 DOI: 10.1111/bjh.16451

Forschung zu COVID-19

• Prolonged Course of COVID-19-Associated Pneumonia in a B-Cell Depleted Patient After Rituximab.
  Igor Kos, Benedikt Balensiefer, Sophie Roth, Manfred Ahlgrimm, Martina Sester, Tina Schmidt, Lorenz Thurner, Moritz Bewarder, Robert Bals, Frank Lammert, Stephan Stilgenbauer, Dominic Kaddu-Mulindwa. Front Oncol 2020 Sep 2;10:1578.    
  PMID: 32984017 PMCID: PMC7493633 DOI: 10.3389/fonc.2020.01578

 

Arbeitsgruppenübergreifende Forschung

• Characterization of an HLA-restricted and human cytomegalovirus-specific antibody repertoire with therapeutic potential.
  Bewarder M, Held G, Thurner L, Stilgenbauer S, Smola S, Preuss KD, Carbon G, Bette B, Christofyllakis K, Bittenbring JT, Felbel A, Hasse A, Murawski N, Kaddu-Mulindwa D, Neumann F.  Cancer Immunol Immunother. 2020 Apr 16.      
  PMID: 32300857 PMCID: PMC7347513 DOI: 10.1007/s00262-020-02564-1

• Insertion site of central venous catheter correlates with catheter-related infectious events in patients undergoing intensive chemotherapy
  Rixecker T, Lesan V, Ahlgrimm M, Thurner L, Bewarder M, Murawski N, Christofyllakis K, Altmeyer S, Bick A, Stilgenbauer S, Bittenbring JT, Kaddu-Mulindwa D.. Bone Marrow Transplant. 2021 Jan;56(1):195-201.      PMID: 32704092 DOI: 10.1038/s41409-020-01003-0
• Landscape of 4D Cell Interaction in Hodgkin and Non-Hodgkin Lymphomas
  Sylvia Hartmann, Sonja Scharf, Yvonne Steiner, Andreas G. Loth, Emmanuel Donnadieu, Nadine Flinner, Viola Poeschel, Stephanie Angel, Moritz Bewarder, Julia Bein, Uta Brunnberg, Alessandro Bozzatto, Bernhard Schick, Stephan Stilgenbauer, Rainer M. Bohle, Lorenz Thurner and Martin-Leo Hansmann.. Cancers, accepted Oct 12th, 2021 Cancers . 2021 Oct 17;13(20):5208 
  PMID: 34680356 PMCID: PMC8534096 DOI: 10.3390/cancers13205208
• Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.
  Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MR.
  Cancer Discov. 2020 Mar;10(3):440-459. doi: 10.1158/2159-8290.CD-19-0116. Epub 2020 Jan 8.
  PMID: 31915197 Free PMC article. PMCID: PMC7275250 DOI: 10.1158/2159-8290.CD-19-0116
• An Autologous culture model of nodal B cell lymphoma identifies ex vivo determinants of response to bispecific antibodies
  Roider T, Brinkmann BJ, Kim V, Knoll M, Kolb C, Roessner PM, Bordas M, Dreger P, Müller-Tidow C, Huber W, Seiffert M, Dietrich S. Blood Adv. 2021 in press PMID: 34587238 DOI: 10.1182/bloodadvances.2021005400
• Dissecting intratumor heterogeneity of nodal B cell lymphomas on the transcriptional, genetic, and drug response level.
  Roider T, Seufert J, Uvarovskii A, Frauhammer F, Bordas M, Abedpour N, Stolarczyk M, Mallm JP, Rabe R, Bruch PM, Balke-Want H, Hundemer M, Rippe K, Goeppert B, Seiffert M, Brors B, Mechtersheimer G, Zenz T, Peifer M, Chapuy B,  Schlesner M, Müller-Tidow C, Fröhling S,  Huber W,  Anders SA,  Dietrich S. 
  Nature Cell Biology. 2020 PMID: 32541878 DOI: 10.1038/s41556-020-0532-x